Target species: Human
Recombinant protein – lyophilized
- Reconstitute with 50 ul of distilled water.
- Care must be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommends that the vial be mixed gently after reconstitution.
Buffer solution: 0.01 M sodium acetate
- 0.34 M mannitol
- 0.9% Human Serum Albumin
270 x 106 IU / mg, as determined in a viral resistance test
Approx. Protein Concentrations
Total protein concentration 0.1 mg / ml after reconstitution.
- Before reconstitution, store at + 4oC.
- After reconstitution, store at -20oC.
- Storage in frost-free freezers is not recommended. This product must be stored undiluted. Avoid repeated freezing and thawing as this can denature the protein. If this product contains a precipitate, we recommend microcentrifuge before use.
12 months from the date of shipment
The number of clinical visits for condylomata acuminata (genital warts) has increased substantially over the last 30 years. Most infections cause benign lesions, but some types can be associated with cancers of the cervix and penis. Interferons (IFN) have shown antiviral properties for these infections and IFN-beta, in particular, has shown a specific cytopathic effect in humans. A total of 124 patients with condylomata acuminata, most of whom had failed previous therapy, were treated intralesionally with recombinant human interferon-beta-la (r-hIFN-beta-1a) or placebo.
Up to 6 lesions were treated in each patient and injections were performed 3 times per week for a total of 9 injections. Then the patients were followed for 3 months. Efficacy evaluations at all time points (day 19, week 6, and month 3) showed a clear advantage for interferon-beta r-hIFN-beta-1a treatment. Patients who received r-hIFN-beta-1a showed a higher rate of treatment success in terms of complete or partial reduction (at least 50%) of the total area of the treated lesions. The treatment was also well-tolerated.
Headache, flu-like symptoms, and asthenia were more common in patients receiving r-hIFN-beta-1a, but these adverse events were generally mild in severity and rarely led to patient withdrawal. . It was concluded that r-hIFN-beta-1a has good efficacy in condylomata acuminata and, therefore, presents a useful therapeutic alternative in this difficult-to-treat condition.